TY - JOUR
T1 - Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors
AU - Martin, Alexandra L.
AU - Anadon, Carmen M.
AU - Biswas, Subir
AU - Mine, Jessica A.
AU - Handley, Katelyn F.
AU - Payne, Kyle K.
AU - Mandal, Gunjan
AU - Chaurio, Ricardo A.
AU - Powers, John J.
AU - Sprenger, Kimberly B.
AU - Rigolizzo, Kristen E.
AU - Innamarato, Patrick
AU - Harro, Carly M.
AU - Mehta, Sumit
AU - Perez, Bradford A.
AU - Wenham, Robert M.
AU - Conejo-Garcia, Jose R.
N1 - Publisher Copyright: © 2022 American Association for Cancer Research.
PY - 2022/7
Y1 - 2022/7
N2 - Although chimeric antigen receptor (CAR)-expressing T cells have proven success in hematologic malignancies, their effectiveness in solid tumors has been largely unsuccessful thus far. We found that some olfactory receptors are expressed in a variety of solid tumors of different histologic subtypes, with a limited pattern of expression in normal tissues. Quantification of OR2H1 expression by qRT-PCR and Western blot analysis of 17 normal tissues, 82 ovarian cancers of various histologies, eight non-small cell lung cancers (NSCLCs), and 17 breast cancers demonstrated widespread OR2H1 expression in solid epithelial tumors with expression in normal human tissues limited to the testis. CAR T cells recognizing the extracellular domain of the olfactory receptor OR2H1 were generated with a targeting motif identified through the screening of a phage display library and demonstrated OR2H1-specific cytotoxic killing in vitro and in vivo, using tumor cells with spontaneous expression of variable OR2H1 levels. Importantly, recombinant OR2H1 IgG generated with the VH/VL sequences of the CAR construct specifically detected OR2H1 protein signal in 60 human lung cancers, 40 ovarian carcinomas, and 73 cholangiocarcinomas, at positivity rates comparable with mRNA expression and without OR2H1 staining in 58 normal tissues. CRISPR/Cas9-mediated ablation of OR2H1 confirmed targeting specificity of the CAR and the tumor-promoting role of OR2H1 in glucose metabolism. Therefore, T cells redirected against OR2H1-expressing tumor cells represent a promising therapy against a broad range of epithelial cancers, likely with an admissible toxicity profile.
AB - Although chimeric antigen receptor (CAR)-expressing T cells have proven success in hematologic malignancies, their effectiveness in solid tumors has been largely unsuccessful thus far. We found that some olfactory receptors are expressed in a variety of solid tumors of different histologic subtypes, with a limited pattern of expression in normal tissues. Quantification of OR2H1 expression by qRT-PCR and Western blot analysis of 17 normal tissues, 82 ovarian cancers of various histologies, eight non-small cell lung cancers (NSCLCs), and 17 breast cancers demonstrated widespread OR2H1 expression in solid epithelial tumors with expression in normal human tissues limited to the testis. CAR T cells recognizing the extracellular domain of the olfactory receptor OR2H1 were generated with a targeting motif identified through the screening of a phage display library and demonstrated OR2H1-specific cytotoxic killing in vitro and in vivo, using tumor cells with spontaneous expression of variable OR2H1 levels. Importantly, recombinant OR2H1 IgG generated with the VH/VL sequences of the CAR construct specifically detected OR2H1 protein signal in 60 human lung cancers, 40 ovarian carcinomas, and 73 cholangiocarcinomas, at positivity rates comparable with mRNA expression and without OR2H1 staining in 58 normal tissues. CRISPR/Cas9-mediated ablation of OR2H1 confirmed targeting specificity of the CAR and the tumor-promoting role of OR2H1 in glucose metabolism. Therefore, T cells redirected against OR2H1-expressing tumor cells represent a promising therapy against a broad range of epithelial cancers, likely with an admissible toxicity profile.
UR - http://www.scopus.com/inward/record.url?scp=85133588834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133588834&partnerID=8YFLogxK
U2 - https://doi.org/10.1158/1535-7163.MCT-21-0872
DO - https://doi.org/10.1158/1535-7163.MCT-21-0872
M3 - Article
C2 - 35499393
SN - 1535-7163
VL - 21
SP - 1184
EP - 1194
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 7
ER -